Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?

Seth C Inzaule^{1

2}, Tobias F Rinke de Wit^{1

2}, Raph L Hamers^{1

3

4

5}; Pan-African Studies to Evaluate Resistance

Affiliations

¹ Amsterdam Institute for Global Health and Development, Department of Global Health, Amsterdam University Medical Center, University of Amsterdam.
² Joep Lange Institute, Amsterdam, The Netherlands.
³ Eijkman-Oxford Clinical Research Unit, Eijkman Institute for Molecular Biology.
⁴ Faculty of Medicine, Universitas Indonesia, Jakarta.
⁵ Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom.

Comment

Seth C Inzaule et al. Clin Infect Dis. 2019.

. 2019 May 30;68(12):2158-2160.

doi: 10.1093/cid/ciy1070.

Seth C Inzaule^{1

2}, Tobias F Rinke de Wit^{1

2}, Raph L Hamers^{1

3

4

5}; Pan-African Studies to Evaluate Resistance

¹ Amsterdam Institute for Global Health and Development, Department of Global Health, Amsterdam University Medical Center, University of Amsterdam.
² Joep Lange Institute, Amsterdam, The Netherlands.
³ Eijkman-Oxford Clinical Research Unit, Eijkman Institute for Molecular Biology.
⁴ Faculty of Medicine, Universitas Indonesia, Jakarta.
⁵ Center for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom.

No abstract available

Comment on

Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial.
Derache A, Iwuji CC, Baisley K, Danaviah S, Marcelin AG, Calvez V, de Oliveira T, Dabis F, Porter K, Pillay D. Derache A, et al. Clin Infect Dis. 2019 Jul 2;69(2):207-214. doi: 10.1093/cid/ciy881. Clin Infect Dis. 2019. PMID: 30321314 Free PMC article.